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have low positive predictive value, need further development,
and costs and consequences of screening are not fully known.
METHODS: We entered economic/clinical data and expert
opinion into a clinical decision model in order to compare: 1).
Targeted screening (TS) of children with one or more risk factors
for hearing disorders; 2). Universal neonatal hearing screening
(UNHS) by automated auditory brainstem response (AABR);
and 3). UNHS by otoacoustic emission (OAE) testing. RESULTS:
1). TS detected fewer than 15% of cases of bilateral hearing
impairment; 2). AABR-based UNHS was the most efﬁcient but
also costly strategy; and 3). OAE-based UNHS gave a higher
number of false positives than strategy two did. Results were sen-
sitive to prevalence, lost-to-follow-up rates, and costs. CON-
CLUSIONS: About 1 to 3 children/1000 in France are born with
at least moderate bilateral hearing impairment which should be
detected and treated early for normal development (speech, cog-
nitive and social functions). Our results for France conﬁrm pub-
lished data for other countries and can help our decision-makers
prioritize screening strategies. However, longer term dynamic
modeling is needed.
EAR—Patient Reported Outcomes
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OBJECTIVES: To compare parent-reported outcomes for chil-
dren receiving either cefdinir (Omnicef®) or amoxicillin/clavu-
lanate (Augmentin ES-600®) oral suspensions for the treatment
of acute otitis media. Outcomes of satisfaction, tolerability, com-
pliance and work/daycare missed were assessed using the Otitis
Parent Questionnaire (OPQ). METHODS: In a phase 4, single-
blind, parallel-group, randomized, multi-center study designed
to compare safety and efﬁcacy of cefdinir oral suspension (7
mg/kg/day every 12 hours for 10 days) to amoxicillin/clavulanate
oral suspension (90/6.4mg/kg/day amoxicillin base every 12
hours for 10 days), parents or legally authorized representatives
of patients were asked to complete the OPQ, 12–15 days after
the ﬁrst dose of treatment. RESULTS: The intent-to-treat popu-
lation included 311 patients, with a mean age of 37 months.
Parents reported signiﬁcantly better ease of use and taste in the
cefdinir vs. the amoxicillin/clavulanate treatment groups (both 
p < 0.0001); parents were satisﬁed or very satisﬁed with the ease
of use (89%) and with the taste of cefdinir (85%) as compared
with amoxicillin/clavulanate (57% and 39%, respectively). Chil-
dren were more likely to take their medication in the cefdinir
group compared to the amoxicillin/clavulanate group: parents
reported 82% of children took at least 95% of their doses of cef-
dinir, while 61% took at least 95% of the prescribed dose of
amoxicillin/clavulanate (p < 0.0001). Parent reported data sug-
gested that their children were signiﬁcantly more likely to expe-
rience diarrhea/loose stools in the amoxicillin/clavulanate group
than in the cefdinir group (28% vs. 18%; p = 0.0341). There
were no statistically signiﬁcant differences in work/daycare
missed. CONCLUSIONS: Based on parents’ assessments using
the OPQ, cefdinir was easier to administer and better tasting.
Children who received cefdinir experienced less vomiting and
diarrhea/loose stools. In addition, these children were reported
to be more compliant than those who received amoxicillin/
clavulanate.
EYE—Clinical Outcomes Studies
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OBJECTIVES: In France, the prevalence of primary open angle
glaucoma has been estimated at 2% of the population over 40
years old. Given the limited data available, we prompted an epi-
demiological survey on the prevalence of ocular hypertension
and high pressure glaucoma in France. The principal objective
of this survey was to evaluate the prevalence of ocular hyper-
tension and high pressure glaucoma in subjects who were vol-
unteers for a health assessment, and to ﬁnd some risk factors.
METHOD: Clinical and laboratory data were collected during
the screening program, as well as information on the way of life,
and the personal and family medical history. All volunteers were
subjected to an intra ocular pressure, IOP recording with an air
tonometer. Those with an IOP above 21 mm Hg underwent a
FDT (frequence dubling technology) visual ﬁeld and a non
stereoscopic photograph with a digital non mydriatic camera.
Among 2797 subjects, 2165 subjects (i.e. 77.4%) agreed to par-
ticipate. Altogether, 2074 subjects (1384 men and 690 women)
were included in the study. RESULTS: Intraocular pressure >21
mmHg was observed in 10.1% of men and 6.4% of women. This
prevalence increased with age. Glaucoma was conﬁrmed in 2.2%
of men and in 3.0% of women. Prevalence of glaucoma in men
varied between 0.8% in the youngest subjects and 5.7% in sub-
jects over 60 years, and between 0.6% and 4.7%, respectively
in women. Logistic regression demonstrated that few parameters
of the health assessment could be linked to intraocular pressure
or glaucoma. CONCLUSION: This cross sectional study demon-
strated that there is a higher prevalence of ocular hypertension
and high pressure glaucoma than reported in currently published
data. This study did not reveal any major factors that could be
linked to ocular hypertension and glaucoma.
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OBJECTIVES: The objective of the present study is to estimate
the prevalence of treatment with intraocular pressure (IOP) low-
ering topical medication in subjects aged 40 years or more in
continental France, and to describe the type of therapy, the com-
pliance and quality of life of the treated subjects. METHODS:
This is a telephone survey performed in general population on a
representative sample of 5726 subjects during the year 2004.
Subjects treated for glaucoma or HTO were deﬁned as those:
declaring using eye drops for more than one month and 1) citing
one of the 52 registered IOP-lowering topical medications,
and/or 2) declaring that they were taking the eye drops for glau-
coma or ocular hypertension (OHT). Quality of life was 
measured using the GlauQOL-17 questionnaire. RESULTS:
Globally, 237 subjects (4.1%) corresponded to this deﬁnition.
The prevalence increased with age, from 0.7% in subjects aged
40–44 years to 10.6% in those aged 80 years or more. 
Beta-blockers (49.5%) and prostaglandins (37.4%) were the
more frequent treatments, followed by carbonic anhydrase
inhibitors (15.3%), sympathomimetic mydriatics (5.7%) and
myotics (1.3%). Compliance was not total for 39% of the
